1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience

BACKGROUND: Letermovir (LTV) is approved for the prevention of CMV infection in CMV seropositive (R+) HCT recipients. Low rates of CMV breakthrough viremia have been reported with LTV prophylaxis. We studied the kinetics of CMV reactivation up to day (D) +100 in patients (patients) receiving LTV pro...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Open Forum Infect Dis
Asıl Yazarlar: Zavras, Phaedon D, Stern, Anat, Su, Yiqi, Fang, Jiaqi, Giralt, Sergio, Perales, Miguel, Maloy, Molly, Seo, Susan K, Papanicolaou, Genovefa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809059/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1605
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller